To assess the safety and tolerability of Rituximab in Graves' dysthyroid disease up to 24 weeks. Adverse and serious adverse events during the study period, reasonably or probably related to Rituximab, will be assessed at each study visit up to 12 month

Since this is an evaluation and treatment and repository protocol, there are no formal outcomes to be measured; however all patients in the NEI clinic have visual acuity measured at every visit, so this can be used as a measure of adverse exper...

1250

All

Child, Adult, Older Adult

NCT02471287

15012815-EI-0128

June 12, 2015

May 1, 2020

May 1, 2020

June 15, 2015

January 15, 2019

National Institutes of Health Clinical Center, 9000 Rockville PikeBethesda, Maryland, United States

Assessment, by the determination of the Cohen's kappa coefficient, of the concordance between the conventional sequences (T1, T2, T2-fat-sat) and the mDIXON sequence for the diagnosis of inflammatory or non-inflammatory dysthyroid orbitopathy.